Day: November 16, 2024

Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater TTR reduction may lead to a greater clinical benefit in ATTR amyloidosis Favorable trends consistently observed across multiple markers of cardiac disease progression at month 12 compared to baseline in an ATTR-CM population with a high proportion of advanced heart failure patients Consistent trend observed to date in ATTRv-PN arm, with stability or improvement of neuropathy as measured by multiple clinical measures of disease progression compared to baseline Persistently deep levels of serum TTR reductions following a single infusion remain virtually unchanged after two or more years of follow-up in over 25 patients Favorable safety and...

Two New Analyses from SEQUOIA-HCM Demonstrate Treatment with Aficamten Improves Post-Exercise Oxygen Uptake Recovery and Quality of Life New Data from FOREST-HCM Demonstrate Aficamten Durably Reduces the Proportion of Patients Guideline Eligible for Septal Reduction Therapy Analyses of Real-World Data Reveal Cost of Care Differences in HCM Across Gender, Age and Race/Ethnicity SOUTH SAN FRANCISCO, Calif., Nov. 16, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data relating to aficamten and hypertrophic cardiomyopathy (HCM), were presented at the American Heart Association Scientific Sessions 2024 in Chicago, IL. “These analyses add to the growing body of evidence supporting the safety and efficacy profile of aficamten and build upon primary findings related to peak VO2 and improvement in...

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from post-hoc analyses of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 cardiovascular outcomes clinical trial of omecamtiv mecarbil were presented at the American Heart Association Scientific Sessions 2024 in Chicago, IL. “These analyses reinforce the potential treatment benefit of omecamtiv mecarbil in patients from GALACTIC-HF who are at higher risk, such as older patients or those with a recent ventricular arrhythmia,” said Stuart Kupfer, M.D., Senior Vice President, Chief Medical Officer. “As we prepare for the start of COMET-HF, the confirmatory Phase 3 clinical trial of omecamtiv mecarbil, we look forward to evaluating...

Check out the highlights in the B-Box Journey!SHENZHEN, China, Nov. 16, 2024 (GLOBE NEWSWIRE) — BYD Co. Ltd., expands the partner program for BYD Energy Storage solutions. As part of the program, BYD held a partner conference at the BYD headquarters in November 2024, in which partners had the opportunity to voice their experiences, have an exchange with the technical team and receive an exclusive preview on upcoming new products and features.“BYD has been investing continuously into R&D as well as the production facilities to make sure energy storage solutions are not only at the forefront of the innovation curve but also produced with the highest safety standards and in a cost-efficient way,” said Yin Xiaoqiang, GM of BYD Energy Storage. “Another important factor in our product development is active...

Check out the highlights in the B-Box Journey!SHENZHEN, China, Nov. 16, 2024 (GLOBE NEWSWIRE) — BYD Co. Ltd., expands the partner program for BYD Energy Storage solutions. As part of the program, BYD held a partner conference at the BYD headquarters in November 2024, in which partners had the opportunity to voice their experiences, have an exchange with the technical team and receive an exclusive preview on upcoming new products and features.“BYD has been investing continuously into R&D as well as the production facilities to make sure energy storage solutions are not only at the forefront of the innovation curve but also produced with the highest safety standards and in a cost-efficient way,” said Yin Xiaoqiang, GM of BYD Energy Storage. “Another important factor in our product development is active...

SHANGHAI, Nov. 16, 2024 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its wholly-owned subsidiary, TopAlliance Biosciences Inc. (TopAlliance Biosciences), announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved toripalimab (UK trade name: LOQTORZI®) for the treatment of two indications:Toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma (NPC); Toripalimab in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with...

The Prospectus Supplement and Base Shelf Prospectus are accessible through SEDAR+ NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR THE DISSEMINATION, DISTRIBUTION, RELEASE OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES VANCOUVER, British Columbia, Nov. 15, 2024 (GLOBE NEWSWIRE) — DMG Blockchain Solutions Inc. (TSXV: DMGI) (“DMG” or the “Company”) is pleased to announce that it has filed its prospectus supplement dated November 14, 2024 (the “Prospectus Supplement”) to the Company’s short form base shelf prospectus dated October 1, 2024 (the “Base Shelf Prospectus“) in each of the provinces of Canada, except Quebec, in respect of its previously announced overnight marketed offering (the “Offering”) of 28,310,000 units of the Company (the “Units”) at a price of $0.53 per Unit for aggregate...

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 15, 2024 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE: VERS) (OTCQB:VRSSF) (“VERSES” or the “Company”) is pleased to announce that it closed the second tranche of its previously announced non-brokered private placement (the “LIFE Offering“) of units of the Company (the “LIFE Units“) for aggregate gross proceeds in this second tranche of $512,800. The first tranche of the LIFE Offering closed on November 8, 2024 for aggregate gross proceeds of $2,903,850. On November 8, 2024 the Company also closed a non-brokered private placement of special warrants of the Company for aggregate gross proceeds of $1,800,000. Pursuant to the second tranche of the LIFE Offering, the Company...

GUANGZHOU, China, Nov. 15, 2024 (GLOBE NEWSWIRE) — Highest Performances Holdings Inc. (NASDAQ: HPH) (“HPH” or the “Company”), today announced that it has filed its annual report for the fiscal year ended June 30, 2024 on Form 20-F (the “FY2024 20-F”), which contains its audited financial statements for the fiscal year ended June 30, 2024, with the U.S. Securities and Exchange Commission (the “SEC”) on November 15, 2024. The FY2024 20-F can be accessed on the SEC’s website at http://www.sec.gov as well as on the Investor Relations page of the Company’s website at https://ir.puyiwm.com/financial-information/sec-filings. Hard copies of the annual report are available, free of charge, to its shareholders upon request. About HPHFounded in 2010 and formerly known as Puyi Inc., we have evolved with a vision to become a leading provider...